Kintara Therapeutics (KTRA)
(Delayed Data from NSDQ)
$0.27 USD
-0.01 (-3.60%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $0.27 0.00 (-0.04%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KTRA 0.27 -0.01(-3.60%)
Will KTRA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for KTRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KTRA
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
KTRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KTRA
12 Health Care Stocks Moving In Friday's Pre-Market Session
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
12 Health Care Stocks Moving In Thursday's After-Market Session
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
12 Health Care Stocks Moving In Tuesday's Intraday Session